Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies
Bio-Rad Laboratories (NYSE: BIO) has announced a binding offer to acquire Stilla Technologies, a developer of next-generation digital PCR solutions. The acquisition, expected to close by the end of Q3 2025, aims to complement Bio-Rad's existing digital PCR portfolio.
Stilla, operating in France and the U.S., develops the Nio® family of all-in-one digital PCR systems, which supports genetic testing across multiple applications including liquid biopsy, oncology diagnostics, cell and gene therapy, organ transplant testing, infectious diseases, and food and environmental testing.
The integration would enhance Bio-Rad's capabilities in applied research and clinical diagnostics, particularly in areas requiring higher automation and throughput. Together with Bio-Rad's planned launch of the QX Continuum™ system, the combined platforms would serve a full range of digital PCR applications in genomics research and applied science.
Bio-Rad Laboratories (NYSE: BIO) ha annunciato un'offerta vincolante per acquisire Stilla Technologies, un sviluppatore di soluzioni di PCR digitale di nuova generazione. L'acquisizione, prevista per concludersi entro la fine del terzo trimestre del 2025, mira a completare il portafoglio esistente di PCR digitale di Bio-Rad.
Stilla, operante in Francia e negli Stati Uniti, sviluppa la famiglia Nio® di sistemi di PCR digitale tutto-in-uno, che supporta il testing genetico in diverse applicazioni, tra cui biopsia liquida, diagnostica oncologica, terapia cellulare e genica, test di trapianto d'organo, malattie infettive e test alimentari e ambientali.
L'integrazione migliorerebbe le capacità di Bio-Rad nella ricerca applicata e nella diagnostica clinica, in particolare nelle aree che richiedono maggiore automazione e capacità di elaborazione. Insieme al previsto lancio del QX Continuum™ system da parte di Bio-Rad, le piattaforme combinate servirebbero un'ampia gamma di applicazioni di PCR digitale nella ricerca genomica e nella scienza applicata.
Bio-Rad Laboratories (NYSE: BIO) ha anunciado una oferta vinculante para adquirir Stilla Technologies, un desarrollador de soluciones de PCR digital de nueva generación. Se espera que la adquisición se cierre a finales del tercer trimestre de 2025 y tiene como objetivo complementar el portafolio existente de PCR digital de Bio-Rad.
Stilla, que opera en Francia y EE. UU., desarrolla la familia Nio® de sistemas de PCR digital todo-en-uno, que apoya la prueba genética en múltiples aplicaciones, incluyendo biopsia líquida, diagnóstico oncológico, terapia celular y génica, pruebas de trasplante de órganos, enfermedades infecciosas y pruebas alimentarias y ambientales.
La integración mejoraría las capacidades de Bio-Rad en investigación aplicada y diagnóstico clínico, particularmente en áreas que requieren mayor automatización y rendimiento. Junto con el lanzamiento planeado del QX Continuum™ system por parte de Bio-Rad, las plataformas combinadas atenderían una amplia gama de aplicaciones de PCR digital en investigación genómica y ciencia aplicada.
바이오래드 연구소 (NYSE: BIO)는 차세대 디지털 PCR 솔루션 개발업체인 스틸라 테크놀로지스 인수에 대한 구속력 있는 제안을 발표했습니다. 이번 인수는 2025년 3분기 말까지 완료될 예정이며, 바이오래드의 기존 디지털 PCR 포트폴리오를 보완하는 것을 목표로 하고 있습니다.
프랑스와 미국에서 운영되는 스틸라는 액체 생검, 종양학 진단, 세포 및 유전자 치료, 장기 이식 검사, 감염병 및 식품 및 환경 검사 등 다양한 응용 분야에서 유전자 검사를 지원하는 Nio® 패밀리의 올인원 디지털 PCR 시스템을 개발합니다.
이번 통합은 특히 자동화 및 처리량이 더 필요한 분야에서 바이오래드의 응용 연구 및 임상 진단 능력을 향상시킬 것입니다. 바이오래드의 QX Continuum™ 시스템 출시 계획과 함께, 통합 플랫폼은 유전체 연구 및 응용 과학에서 디지털 PCR의 모든 응용 프로그램을 지원할 것입니다.
Bio-Rad Laboratories (NYSE: BIO) a annoncé une offre contraignante pour acquérir Stilla Technologies, un développeur de solutions de PCR numérique de nouvelle génération. L'acquisition, qui devrait être finalisée d'ici la fin du troisième trimestre 2025, vise à compléter le portefeuille existant de PCR numérique de Bio-Rad.
Stilla, opérant en France et aux États-Unis, développe la famille Nio® de systèmes de PCR numérique tout-en-un, qui prend en charge les tests génétiques dans de nombreuses applications, y compris la biopsie liquide, le diagnostic oncologique, la thérapie cellulaire et génique, les tests de transplantation d'organes, les maladies infectieuses et les tests alimentaires et environnementaux.
L'intégration améliorerait les capacités de Bio-Rad en recherche appliquée et en diagnostic clinique, en particulier dans les domaines nécessitant une plus grande automatisation et un meilleur débit. Avec le lancement prévu du QX Continuum™ system par Bio-Rad, les plateformes combinées serviraient un large éventail d'applications de PCR numérique dans la recherche génomique et la science appliquée.
Bio-Rad Laboratories (NYSE: BIO) hat ein verbindliches Angebot zur Übernahme von Stilla Technologies angekündigt, einem Entwickler von digitalen PCR-Lösungen der nächsten Generation. Der Abschluss der Übernahme wird bis Ende des dritten Quartals 2025 erwartet und soll das bestehende digitale PCR-Portfolio von Bio-Rad ergänzen.
Stilla, tätig in Frankreich und den USA, entwickelt die Nio®-Familie von All-in-One-Digital-PCR-Systemen, die genetische Tests in verschiedenen Anwendungen unterstützt, darunter flüssige Biopsie, onkologische Diagnostik, Zell- und Gentherapie, Organtransplantationstests, Infektionskrankheiten sowie Lebensmittel- und Umwelttests.
Die Integration würde die Fähigkeiten von Bio-Rad in der angewandten Forschung und klinischen Diagnostik verbessern, insbesondere in Bereichen, die eine höhere Automatisierung und Durchsatz erfordern. Zusammen mit dem geplanten Start des QX Continuum™-Systems von Bio-Rad würden die kombinierten Plattformen ein vollständiges Spektrum an digitalen PCR-Anwendungen in der Genomforschung und angewandten Wissenschaft bedienen.
- Strategic expansion into applied research and clinical diagnostics markets
- Enhancement of digital PCR portfolio with complementary technology
- Access to Stilla's next-generation digital PCR systems and consumables
- Geographic expansion through Stilla's operations in France and U.S.
- Regulatory approvals still pending
- Extended closing timeline (Q3 2025)
- Integration risks with existing operations
Insights
This strategic acquisition signals Bio-Rad's aggressive move to consolidate its position in the rapidly growing digital PCR market, estimated to reach
The acquisition's timing is particularly strategic as the digital PCR market enters a critical growth phase, driven by increasing demand in oncology diagnostics, cell and gene therapy, and infectious disease testing. Stilla's expertise in developing automated, all-in-one systems directly addresses the market's shift toward simplified workflows and increased throughput capabilities.
Key synergistic opportunities include:
- Expanded market access in Europe through Stilla's established French operations
- Cross-selling opportunities across Bio-Rad's existing customer base
- Accelerated R&D capabilities through combined intellectual property portfolios
- Enhanced competitive positioning against industry leaders like Thermo Fisher and QIAGEN
The expected closing by Q3 2025 suggests a thorough regulatory review process, particularly given the sensitive nature of diagnostic technology transfers. Integration risks appear manageable given Bio-Rad's track record in acquisitions and the complementary nature of Stilla's technology.
This acquisition reflects broader industry consolidation trends where established players are acquiring innovative technologies to maintain competitive advantages in precision diagnostics. The combined entity would be well-positioned to capture growing demand in emerging applications like liquid biopsy and cell therapy quality control.
Transaction To Complement Bio-Rad’s Existing Digital PCR Portfolio and Accelerate Development of Next-Generation Digital PCR Solutions
With operations in
"Stilla’s next-generation digital PCR solutions would make a compelling and complementary addition to Bio-Rad’s best-in-class digital PCR portfolio,” said Norman Schwartz, CEO of Bio-Rad Laboratories. “Once closed, the acquisition will support our strategy to further expand our business into applied research and clinical diagnostics where customers expect a higher degree of automation and throughput capabilities.”
Jim Barry, EVP and President of Bio-Rad’s Life Science Group, added, “Together with our planned launch of Bio-Rad’s QX Continuum™ system, the Stilla platform would allow us to serve the full range of digital PCR applications and help us meet the evolving needs of customers in genomics research and applied science.”
Rémi Dangla, CEO of Stilla Technologies, stated, “We are thrilled with the prospect of joining Bio-Rad, a leader in the field of digital PCR. With Stilla’s passion for product development and Bio-Rad’s extensive life science expertise, operational excellence, and global reach, together we can bring substantial value to the work of applied research and biopharma customers around the globe.”
BIO-RAD and QX Continuum are trademarks of Bio-Rad Laboratories, Inc., Nio is a trademark of Stilla Technologies SAS.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in
Bio-Rad Forward-Looking Statements
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our offer to acquire Stilla Technologies. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include, but are not limited to, the timing of the proposed transaction; the possibility that various conditions to the consummation of the proposed transaction may not be satisfied or waived; the ability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing; the effects of disruption from the proposed transaction and the impact of the announcement and pendency of the proposed transaction on Stilla Technologies’ business; the possibility that the anticipated benefits from the proposed transaction cannot be realized in the manner contemplated; the ability to successfully integrate the acquired business into the Company’s operations; the planned launch of our QX Continuum system; and other factors beyond the control of the Company and/or Stilla Technologies. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250213083127/en/
Bio-Rad Investor Contact:
Edward Chung, Investor Relations
510-741-6104
ir@bio-rad.com
Bio-Rad Media Contact:
Anna Gralinska, Corporate Communications
510-741-6643
cc@bio-rad.com
Source: Bio-Rad Laboratories, Inc.
FAQ
When is Bio-Rad's acquisition of Stilla Technologies expected to close?
What products does Stilla Technologies bring to Bio-Rad's portfolio?
How will the Stilla acquisition complement Bio-Rad's existing product line?
What markets will Bio-Rad expand into with the Stilla acquisition?
What applications does Stilla's technology support?
